Lupin gets USFDA’s approval for Testosterone Gel

11 Apr 2019 Evaluate

Lupin has received approval for Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), from the United States Food and Drug Administration (USFDA) to market a generic version of AbbVie, Inc’s (AbbVie) AndroGel 1.62%.

The company’s Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie’s AndroGel, 1.62%. Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), (RLD: AndroGel) had annual sales of approximately $893 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2111.90 -1.25 (-0.06%)
18-Dec-2025 10:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1754.50
Dr. Reddys Lab 1267.80
Cipla 1498.30
Zydus Lifesciences 916.70
Lupin 2111.90
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×